(Q40255550)

English

The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole

scientific article published on 5 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

based on heuristic

inferred from title

invasive fungal infections

1 reference

based on heuristic

inferred from title

8

object named as

Mark R Litzow

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Jason N Barreto

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Cassidy L Beach

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Robert C Wolf

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Julianna A Merten

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Pritish K Tosh

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

John W Wilson

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

William J Hogan

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

publication date

5 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

88

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

283-288

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Towards a targeted, risk-based, antifungal strategy in neutropenic patients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Voriconazole: a new triazole antifungal agent

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Voriconazole therapeutic drug monitoring.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Voriconazole concentrations and outcome of invasive fungal infections

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23388

21 January 2018

Identifiers

10.1002/AJH.23388

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40255550&oldid=1891171175"